Sepideh Taghavi

Prof. Sepideh Taghavi

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 August 2022 in Clinical Case Reports
Verified
Journal Article
Open access
AAAfsaneh Amiri
Afsaneh Amiri
GHGolnaz Houshmand
Golnaz Houshmand
STSepideh Taghavi
Sepideh Taghavi
MKMonireh Kamali
Monireh Kamali
MFMona Faraji
Mona Faraji
NNNasim Naderi
Nasim Naderi
It has been shown that severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), by coronavirus disease 2019 (COVID‐19), can lead to multi‐organ impairment including cardiac involvement and immunological problems. Acute myocarditis is one of serious and fatal complications of COVID‐19. In this case report, we present a 46‐year‐old lady with a history of lichen planus dermatitis who has developed a rapidly progressive heart failure after an episode of COVID‐19. The pathologic examination of her endomyocardial biopsy specimens was compatible with GCM, and she was successfully treated with a combined immunosuppressive therapy regimen.

11 January 2022 in Global Heart
Verified
Journal Article
Open access
PDF file
SHSaeid Hosseini
Saeid Hosseini
NSNiloufar Samiei
Niloufar Samiei
ATAvisa Tabib
Avisa Tabib
HBHooman Bakhshandeh
Hooman Bakhshandeh
YRYOUSEF REZAEI
YOUSEF REZAEI
OIOn Behalf of the SHED LIGHT Investigators
On Behalf of the SHED LIGHT Investigators
Structural heart disease (SHD) has great impacts on healthcare systems, creating further public health concerns. Proper data are scant regarding the magnitude of the affected population by SHD. This study aimed to determine the prevalence of SHD among children and adolescents in an Iranian population. In this population-based study, a multistage cluster-random sampling was used to choose schools from the Tehran urban area. All students were examined using a handheld Vscan device by echocardiographer, and the results were concurrently supervised and interpreted by cardiologists. All the major findings were reevaluated in hospital clinics. Of 15,130 students (6–18 years, 52.2% boys) who were examined, the prevalence of individuals with congenital heart disease (CHD) and cardiomyopathy was 152 (10.046 per 1,000 persons) and 9 (0.595 per 1,000 persons), respectively. The prevalence of definite and borderline rheumatic heart disease (RHD) was 30 (2 per 1,000 persons) and 113 (7.5 per 1,000 persons), correspondingly. Non-rheumatic valvular heart disease (VHD) was also detected in 465 (30.7 per 1,000 persons) students. Of all the pathologies, only 39 (25.6%) cases with CHD and 1 (0.007%) cases with RHD had already been diagnosed. Parental consanguinity was the strongest predictor of CHD and SHD (odds ratio [OR]: 1.907, 95% CI, 1.358 to 2.680; P < 0.001 and OR, 1.855, 95% CI, 1.334 to 2.579; P < 0.001, respectively). The female sex (OR, 1.262, 95% CI, 1.013 to 1.573; P = 0.038) and fathers’ low literacy (OR, 1.872, 95% CI, 1.068 to 3.281; P = 0.029) were the strongest predictors of non-rheumatic VHD and RHD, correspondingly. The implementation of echocardiographic examinations for detecting SHD among young population is feasible which detected SHD prevalence in our population comparable to previous reports. Further studies are required to delineate its economic aspects for community-based screening.

17 December 2022 in Journal of Cardiovascular and Thoracic Research
Verified
Journal Article
Open access
PDF file
STSepideh Taghavi
Sepideh Taghavi
HJHoda Raffiei Jelodar
Hoda Raffiei Jelodar
ARAli Rafati
Ali Rafati
NNNasim Naderi
Nasim Naderi
MMMarzieh Mirtajaddini
Marzieh Mirtajaddini
SNSoroush Naseh
Soroush Naseh
Introduction: After solid organ transplantation, patients require lifelong immunosuppressive medication, increasing susceptibility to COVID-19. We evaluated the clinical outcomes of heart transplant recipients in patients with COVID-19. Methods: We enrolled twenty-two COVID-19 cases of adult heart transplantation from February 2020 to September 2021. Results: The most common symptoms in patients were fever and myalgia. The death occurred in 3 (13.6 %). Conclusion: Although heart transplantation mortality may increase in the acute rejection phase concomitant with COVID-19, immunosuppressive dose reduction may not be necessary for all heart transplant patients with COVID-19.

28 November 2020 in Journal of Cardiovascular and Thoracic Research
Verified
Journal Article
Open access
PDF file
STSepideh Taghavi
Sepideh Taghavi
MCMaryam Chenaghlou
Maryam Chenaghlou
MMMarzieh Mirtajaddini
Marzieh Mirtajaddini
AAAhmad Amin
Ahmad Amin
NNNasim Naderi
Nasim Naderi
Patients with advanced heart failure (HF) symptoms constitute stage D heart failure with high mortality and less response to conventional guideline directed medical therapies. These patients are subjected to receive non-medical therapies including heart transplant or mechanical circulatory support for increasing survival. Considering the low availability and serious complications of these strategies,effective medical therapies for this group of patients would be pivotal for decreasing mortality and morbidity of them. Angiotensin receptor neprilysin inhibitor (ARNI) is a class of drugs approved for ambulatory heart failure patients. ARNI use like other groups of heart failure drugs has not been fully evaluated in end-stage heart failure patients. Herein, we describe four inotrope-dependent heart failure patients. Initiation of ARNI in these patients, lead to discontinuation of inotrope and reducing the need for inotrope in the follow-up period.

12 December 2020 in Multidisciplinary Cardiovascular Annals
Verified
Journal Article
Open access
PDF file
STSepideh Taghavi
Sepideh Taghavi
NNNasim Naderi
Nasim Naderi
AAAhmad Amin
Ahmad Amin
SMSara Mobini
Sara Mobini
ASAmine Safavirad
Amine Safavirad
MMMahfam Malakouti
Mahfam Malakouti
Background: Congestive Heart Failure (CHF) is a debilitating disorder that affects 1-2% of the general population. Despite recent advances in the management of heart failure, symptomatic heart failure still has a poor prognosis, so the importance of evaluating these patients is emphasized. The micronutrients are not produced in the body, but they should be taken in the required amount of diet, and their required amount is generally less than 100 mg per day. Copper deficiency leads to hypertrophic cardiomyopathies in several experimental models, which ultimately leads to systolic and diastolic cardiac function impairment. Copper deficiency is the only nutritional factor that increases cholesterol, blood pressure, homocysteine, and uric acid, leads to glucose intolerance, and increases thrombotic and oxidative damage. Objectives: The aim of this assessment is to examine the serum copper level in patients with Heart failure hospitalized in Rajaie Cardiovascular, Medical and Research Center and its related factors in the period of 2017-18. Methods: This as a prospective descriptive study conducted on patients with heart failure hospitalized in Rajaee Cardiovascular, Medical and Research Center. Research variables included serum copper level, Pro-BNP serum level, heart failure etiology, Seattle Heart Failure Model (SHFM), age, gender, BMI, history of diabetes, history of airway disease, duration of heart failure diagnosis, smoking, presence of shortness of breath, the amount of ejection fraction (EF), initial blood pressure, serum hemoglobin levels, white blood cell count, creatinine, cholesterol, sodium and uric acid. Accordingly, 80 patients with heart failure have been evaluated and the results of the evaluation of patients have been put together based on the aims of the study. Results: Of the evaluated cases, there were 52 (65%) male and 35 (28%) female. The mean and standard deviation of the patients' age was 49.9 ± 16.2 years, also the mean and standard deviation of serum copper was 189.28 ± 58.3 (range:80-150). The evaluated indices in this study included severe NYHA (P = 0.90), ejection fraction (EF) in echocardiography (P = 0.40), serum Pro BNP (P = 0.45) and prognosis of disease according to Seattle Heart Failure Model (P = 0.63), because non of the patients copper serum level were under the baseline we could not found statistically significant relationship between serum copper level and EF, pro BNP, NYHA function class and prognosis of the disease according to Seattle Heart failure model, while there was a significant statistical relationship between serum copper levels and etiology of heart failure (P = 0.02). Conclusions: Copper does not have a significant effect on the status of patients with heart failure, and only some differences were observed in the etiology of heart failure.

11 December 2023 in Clinical Case Reports
Verified
Journal Article
Open access
HGHoda Gharoy
Hoda Gharoy
STSepideh Taghavi
Sepideh Taghavi
ZGZahra Ghaemmaghami
Zahra Ghaemmaghami
PRParham Rabiei
Parham Rabiei
AAAzadeh Afzalnia
Azadeh Afzalnia
Key Clinical Message: In patients presenting with aortic ectasia and myxomatous valve diseases at young ages, possible underlying acromegaly should be in mind. Acromegaly is a chronic systemic disease mainly caused by the benign pituitary adenoma secreting growth hormone (GH) in excess. Acromegaly is associated with various complications such as cardiovascular diseases. In this regard, timely diagnosis, and management of these patients could be life‐saving. Herein, a case of aneurysmal dilation of the sinus of Valsalva with severe aortic and mitral regurgitation in a patient with undiagnosed acromegaly is presented.